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Aureobasidium pullulans is an unusual agent of phaeohyphomycosis. The in vitro activities of antifungals against 104 isolates of
Aureobasidium pullulans var. pullulans and A. pullulans var. melanigenum revealed low MIC90s of amphotericin B, posacona-
zole, and itraconazole. However, they were resistant to fluconazole (>64g/ml) and had high MICs of voriconazole, isavucona-
zole, caspofungin, and micafungin.
Aureobasidium pullulans is a common ubiquitously distributedmelanized yeast-like fungus that is an occasional agent of
phaeohyphomycosis (1). The genus Aureobasidium phylogeneti-
cally belongs to Ascomycota, order Dothideales, family Dothide-
aceae (2, 3). The clinically significant species are A. pullulans (4)
and A. proteae (5); a case of Aureobasidium mansoni associated
with cerebral phaeohyphomycosis (6) probably concerned a mis-
identification. The fungus commonly occurs in the hospital envi-
ronment, where it colonizes moist surfaces, such as glass and
metal, and has recently been reported to cause a varied spectrum
of infections, including peritonitis, meningitis, and fungemia (1).
Although Aureobasidium pullulans has been reported to be the
most common species in over 32 cases of human phaeohyphomy-
cosis infections, so far there are no systematic data on its antifun-
gal susceptibility profiles. Furthermore, the fungus has not been
identified to the species level in the majority of cases reported so
far. Herein we report antifungal susceptibility profiles of 104 mo-
lecularly characterized isolates of Aureobasidium pullulans. The
isolates were obtained from the reference centers Centraalbureau
voor Schimmelcultures, Fungal Biodiversity Centre, Utrecht, The
Netherlands, and the University of Texas Health Science Center,
San Antonio, TX, USA. The strains included currently recognized
varieties with their type strains: Aureobasidium pullulans var. pul-
lulans (n 51) and A. pullulans var.melanigenum (n 53). Most
strains originated from clinical (n 51) and environmental (n
47) samples, while 4 strains were from unknown sources (see Ta-
ble S1 in the supplemental material). Most A. pullulans var.
melanigenum strains (43 of 51) were recovered from clinical spec-
imens, whereas Aureobasidium pullulans var. pullulans strains (40
of 51) were mainly isolated from the environment. Of the clinical
A. pullulans var. melanigenum, 38 isolates (74.5%) were reported
from cases of systemic infections in the United States. Species and
variety identities were confirmed by sequencing the internal tran-
scribed spacer region and the D1/D2 region of the nuclear large
subunit rRNA gene (7).
Antifungal susceptibility testing was performed in duplicate as
per CLSI document M38-A2, with some modifications (8).
Briefly, isolates were cultured on potato dextrose agar in the dark
(25°C) for up to 7 days to induce sporulation. Inocula were pre-
pared by scraping the surface of the fungal colonies with a cotton
swabmoistenedwith sterile physiological saline containing 0.05%
Tween 40. Large particles were allowed to settle for 5 min, and
then a suspension of spores was adjusted with a spectrophotome-
ter (Spectronic 20D; Milton Roy, Rochester, NY) to 68 to 71%
transmission (at 530 nm) and diluted 5-fold to yield a final inoc-
ulumof 1.5 104 to 5 104 CFU/ml as controlled by quantitative
colony counts. Reagent-grade powders of amphotericin B (Bris-
tol-Myers Squibb, Woerden, The Netherlands), itraconazole
(Janssen Research Foundation, Beerse, Belgium), voriconazole
(Pfizer Central, Sandwich, United Kingdom), posaconazole
(Merck, Whitehouse Station, NJ), and isavuconazole (Basilea
Pharmaceuticals, Basel, Switzerland)were used in a concentration
range of 0.016 to 16 g/ml. The fluconazole (Pfizer) concentra-
tion ranged from 0.063 to 64 g/ml, while the caspofungin
(Merck) and micafungin (Astellas Pharma, Ibaraki, Japan) con-
centrations ranged from 0.008 to 8 g/ml. The MIC/minimum
effective concentration (MEC) distributions of A. pullulans var.
pullulans and A. pullulans var. melanigenum were compared by
using the Mann-Whitney-Wilcoxon test for skewed distribution.
A P value of0.05 was considered statistically significant.
Results were read for 95% of isolates after an incubation of 72
h at 25°C and for the remaining isolates, which did not grow
luxuriantly, after 96 h. MICs of amphotericin B, itraconazole,
voriconazole, posaconazole, and isavuconazole were defined visu-
ally as the lowest drug concentration that prevented any discern-
ible growth (100% inhibition), whereas for fluconazole, the MIC
was taken as the lowest concentration supporting 50% growth
inhibition compared to the growth in the control wells. For caspo-
fungin and micafungin, MECs were determined microscopically
Received 16 April 2014 Returned for modification 26 May 2014
Accepted 3 July 2014
Published ahead of print 7 July 2014
Address correspondence to Jacques F. Meis, j.meis@cwz.nl.
Supplemental material for this article may be found at http://dx.doi.org/10.1128
/AAC.03095-14.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.
doi:10.1128/AAC.03095-14
September 2014 Volume 58 Number 9 Antimicrobial Agents and Chemotherapy p. 5629–5631 aac.asm.org 5629
 o
n
 M
ay 1, 2017 by UNIVERSITEITSBIBLIO
THEEK
http://aac.asm
.org/
D
ow
nloaded from
 
as the lowest concentration of drug promoting the growth of
small, round, compact hyphae relative to the appearance of the
filamentous forms seen in the control wells. Quality control
strains of Paecilomyces variotii (ATCC 22319), Candida parapsilo-
sis (ATCC 22019), and Candida krusei (ATCC 6258) were in-
cluded in each assay.
The MIC50, MIC90, and geometric mean (GM) values viz. Au-
reobasidium pullulans var. pullulans and A. pullulans var. melani-
genum are given in Table 1. All isolates had low MICs of ampho-
tericin B (MIC90, 1 g/ml), itraconazole (MIC90, 0.5 g/ml),
and posaconazole (MIC90, 0.5 g/ml). However, the less active
drugs were fluconazole, voriconazole, isavuconazole, micafungin,
and caspofungin. The highest GM MICs were 52.75 g/ml for
fluconazole, followed by 1.29 g/ml for isavuconazole and 1.17
g/ml for caspofungin. In contrast much lower GM MICs were
obtained for voriconazole (0.77g/ml), amphotericin B (0.32g/
ml), micafungin (0.28g/ml), itraconazole (0.17g/ml), and po-
saconazole (0.12 g/ml). Anidulafungin was not tested but is ex-
pected to be comparable to micafungin. Routine testing of
caspofungin for Candida has been cautioned recently because of
large interlaboratory variability (9). During the analyses of this
large collection of Aureobasidium isolates, we did not observe
more than one dilution difference of caspofungin tested in dupli-
cate. We evaluated whether the MIC/MEC values correlated with
the two varieties using Mann-Whitney-Wilcoxon test for skewed
distribution. A statistically significant difference in susceptibilities
between the two varieties was observed for itraconazole, po-
saconazole, isavuconazole, and micafungin (P  0.001) but not
for amphotericin B, fluconazole, voriconazole, and caspofungin
(P  0.05). No differences were recorded between clinical and
environmental isolates.
Most of the clinical isolates tested in this study belonged to A.
pullulans var.melanigenum, which were found to be susceptible to
posaconazole, itraconazole, and amphotericin B. Amphotericin B
has been used successfully to treat A. pullulans infections in cases
of systemic dissemination, meningitis, peritonitis (10), and two
proven cases of fungemia (11, 12). Previously, antifungal suscep-
tibility testing (AFST) of solitary isolates of this fungus reported in
two cases indicated amphotericin B MICs of 0.25 g/ml and 0.5
g/ml (10, 12, 13). Recently published guidelines on treatment of
phaeohyphomycosis (14) also recommend therapy with ampho-
tericin B in cases due to A. pullulans infections. In this study, A.
pullulans isolates were resistant to fluconazole. While there are no
established interpretive criteria for antifungal susceptibilities ofA.
pullulans, the high MICs of all isolates tested suggest fluconazole
resistance. Previously, two cases in which A. pullulans was the
etiologic agent reported both high (64 g/ml) and low (4 g/ml)
MICs of fluconazole (10, 13). Amphotericin B, itraconazole, and
posaconazole were the drugs with the best overall activity. This is
the first comprehensive study on antifungal susceptibility data of a
large number of clinically significant A. pullulans species demon-
strating that the two different varieties of A. pullulans show low
MICs of amphotericin B, itraconazole, and posaconazole, which
supports the therapeutic recommendations published by the Eu-
ropean Society of Clinical Microbiology and Infectious Diseases/
European Confederation of Medical Mycology (ESCMID/
ECMM) (14).
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